Citigroup
BTAI icon

Citigroup’s BioXcel Therapeutics BTAI Stock Holding History

Citigroup’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.23K Buy
+2,998
New +$3.51K ﹤0.01% 5328
2026
Q1 		– Sell
-12,079
Closed -$19.3K – 5969
2025
Q4 		$19.3K Buy
12,079
+11,724
+3,303% +$24.2K ﹤0.01% 4882
2025
Q3 		$909 Buy
+355
New +$1.12K ﹤0.01% 5639
2024
Q4 		– Hold
0
– -$2 – 5845
2024
Q3 		– Sell
-3,486
Closed -$46.8K – 5647
2024
Q2 		$71.4K Buy
3,486
+3,266
+1,485% +$109K ﹤0.01% 4386
2024
Q1 		$9.91K Buy
220
+39
+22% +$1.86K ﹤0.01% 5202
2023
Q4 		$8.53K Sell
181
-1,340
-88% -$74.5K ﹤0.01% 5229
2023
Q3 		$61.6K Sell
1,521
-2,233
-59% -$226K ﹤0.01% 4069
2023
Q2 		$400K Sell
3,754
-3,682
-50% -$1.23M ﹤0.01% 3523
2023
Q1 		$2.22M Buy
7,436
+7,397
+18,967% +$3.16M ﹤0.01% 1947
2022
Q4 		$13.3K Sell
39
-9
-19% -$2.18K ﹤0.01% 4741
2022
Q3 		$9K Sell
48
-67
-58% -$15.6K ﹤0.01% 5020
2022
Q2 		$24K Sell
115
-845
-88% -$178K ﹤0.01% 4885
2022
Q1 		$321K Sell
960
-3,887
-80% -$1.13M ﹤0.01% 3795
2021
Q4 		$1.58M Buy
4,847
+2,387
+97% +$1.02M ﹤0.01% 2811
2021
Q3 		$1.2M Sell
2,460
-4,066
-62% -$1.79M ﹤0.01% 2950
2021
Q2 		$3.03M Buy
6,526
+1,080
+20% +$589K ﹤0.01% 2327
2021
Q1 		$3.76M Buy
5,446
+5,266
+2,926% +$4.24M ﹤0.01% 2013
2020
Q4 		$133K Buy
180
+87
+94% +$67.8K ﹤0.01% 5300
2020
Q3 		$65K Sell
93
-918
-91% -$689K ﹤0.01% 5415
2020
Q2 		$857K Buy
1,011
+881
+678% +$575K ﹤0.01% 3720
2020
Q1 		$46K Buy
130
+43
+49% +$15.5K ﹤0.01% 6032
2019
Q4 		$20K Buy
87
+68
+358% +$6.84K ﹤0.01% 6928
2019
Q3 		$2K Sell
19
-87
-82% -$13.7K ﹤0.01% 7524
2019
Q2 		$18K Buy
106
+6
+6% +$1.02K ﹤0.01% 7119
2019
Q1 		$16K Buy
+100
New +$12.3K ﹤0.01% 7056

Other funds holding BTAI

Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citigroup's BTAI Position: Q2 2026 in Review

Citigroup opened a new position in BioXcel Therapeutics (BTAI) in Q2 2026: 2,998 shares worth $4.23K. The stake represents ﹤0.01% of the portfolio and ranks #5328 among its holdings. This is a return to the name: Citigroup previously reported a position in BTAI as recently as Q4 2025.

Citigroup first reported a position in BTAI in Q1 2019 and has held it in 25 quarters since. The position peaked at $3.76M in Q1 2021. 47 funds tracked by Wall St. Rank hold BTAI as of Q2 2026.

  • Citigroup held 2,998 shares of BioXcel Therapeutics worth $4.23K as of Q2 2026.
  • BioXcel Therapeutics was a new Citigroup position in Q2 2026.
  • BioXcel Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #5328 holding.
  • Citigroup first reported a position in BioXcel Therapeutics in Q1 2019 and has held it in 25 quarters since.
  • Citigroup's BioXcel Therapeutics position peaked at $3.76M in Q1 2021.
  • 47 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.